PubMed HealthSearch

Biomedical subjects

S Villa

Publications and source records attributed to S Villa.

At least 19 recordsLinked to original sources

IHP entrapment into human erythrocytes: comparison between hypotonic dialysis and DMSO osmotic pulse.

Three different blood units were treated separately by the hypotonic dialysis (HD) and the dimethylsulphoxide osmotic pulse (DMSO) method, in order to load the erythrocytes with inositol hexaphosphate. A detailed comparison between the two loading techniques was performed by monitoring the red cell distribution patterns on discontinuous Percoll density gradients, the RBC oxygen affinity and the amount of the main intracellular organic phosphates with the 31P-NMR. The results obtained showed that: (1) The HD loading produces a redistribution of the RBC fractions with a concomitant smoothing of the relative differences among distinct fractions (2) only a minor portion of erythrocytes (from 8.5 to 24.9% of total RBCs) are loaded with IHP after the DMSO treatment. All of these cells move to the lightest fraction (d = 1.080 g/ml). (3) Both HD and DMSO IHP-loaded cells show an increase in P50 (basal vs. after loading, means +/- SD: 25.8 +/- 3.0 vs. 52.5 +/- 3.2 mm Hg) correlated to the IHP incorporation (mean intracellular IHP concentration: 4.2 mmol/l RBC). (4) probably the IHP incorporation efficiency could be probably improved at least by increasing the IHP concentration during the treatment.

Dialysis

[Radiotherapy in the control of bone metastases in patients with adenocarcinoma of the prostate].

Advanced prostatic carcinoma shows a high incidence of bone metastases. This is the main cause of clinical problems such as invalidating bone fractions, collapses and consequently of sharp pain syndromes. In these cases the therapy needs to achieve quick relief of symptoms. Radiotherapy, with its large variety of technical options, allows a wide modulation to fit a lot of clinical situations among the most frequent for these patients. A large series of treatment modalities and related indications will be presented and discussed in this work.

Adenocarcinoma

Platelet aggregation and antithrombin III levels in diabetic children.

We studied platelet function and antithrombrin III levels in 30 insulin-dependent diabetic children with no clinically evident vascular complications. 9 were in-patients and 21 were out-patients. The disease had been discovered within the previous 10 years. 25 control subjects of comparable age and body weight were studied simultaneously. Template bleeding time, threshold concentrations of ADP or adrenaline required to induce irreversible platelet aggregation and plasma antiherparin activity (platelet factor 4) did not differ significantly in control and patient groups. In contrast, the immunological levels of plasma antithrombine III were significantly higher in the diabetic group. These results suggest that diabetic children, with no clinical signs of microanigopathy, show no laboratory changes suggesting increased platelet function. The unxpected increase in the antithrombin III level could reflect a very early defense mechanism against activation of the blood clotting system.

Adenosine Diphosphate

Platelet aggregation: methodology and physiopathology.

The physiopathological role of platelet aggregation in some thromboembolic and atherosclerotic complications is strongly suggested on the basis of many indirect findings. The qualitative methodological approach to this problem generally used until recently is rapidly giving way to a quantitative, biochemical approach. Platelet aggregation, however, even if expressed in terms of nanomoles of a product obtained in a sophisticated reaction system, will continue to deceive investigators and clinicians who fail to view it in the adequate (although still uncertain) context of rheological and vascular interactions.

Animals

Prostacyclin-like activity in rat vascular tissues. Fast, long-lasting inhibition by treatment with lysine acetylsalicylate.

Both arterial and venous tissues obtained from normal rats released prostacyclin (PGI2)-like activity, as marked by its potent inhibitory effect on platelet aggregation. Intraperitoneal or intravenous administration of a single dose of a soluble lysine salt of acetylsalicyclic acid (L-ASA, 1-400 mg/kg) resulted in abolition or substantial reduction of prostacyclin-like activity released from rat vasculature. The inhibitory effect of L-ASA was evident one minute after its i.v. administration to the animals, persisted for at least 24 hours and was still detectable (in venous tissues only) 168 hours later. Venous tissues were inhibited by doses of L-ASA as low as 1 mg/kg, whereas arterial tissues were not inhibited by doses of LA-ASA lower than 10 mg/kg. This difference may possibly be related to the lower prostacyclin-like activity shown by rat venous tissues compared to arterial ones. It is suggested that L-ASA or part of its molecule may bind to and inhibit cyclo-oxygenase in the blood vessel wall in a manner similar to the acetylation of platelt cyclo-oxygenase.

Animals

Bioavailability and platelet aggregation inhibitory activity of solufenum. A comparison with ibuprofen.

Bioavailability and platelet aggregation inhibitory activity of the lysine salt of ibuprofen (solufenum) were compared with those of the parent molecule in 5 healthy male volunteers. The study had a randomized, cross-over design. The average peak plasma level and the area under the curve were higher when solufenum was administered orally as compared to the same preparation given i.m. or as compared to oral ibuprofen. However, the bioavailability of the 3 preparations studied was not significantly different. In contrast, the inhibitory effect on adrenaline-induced platelet aggregation appeared significantly different. In contrast, the inhibitory effect on adrenaline-induced platelet aggregation appeared significantly earlier after the administration of both solufenum than after ibuprofen. The clinical relevance of these findings is discussed.

Adult